Partner Therapeutics, Inc.
9
1
2
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 90/100
33.3%
3 terminated/withdrawn out of 9 trials
57.1%
-29.4% vs industry average
0%
0 trials in Phase 3/4
50%
2 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
Phase II Trial to Evaluate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer's Disease
Role: collaborator
Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers
Role: lead
Biomarker Validation Following Sargramostim Treatment in Parkinson's Disease
Role: collaborator
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)
Role: lead
A Study of Sargramostim Plus Pembrolizumab with or Without Pemetrexed in Patients with Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy
Role: collaborator
Sargramostim With Ipilimumab Containing Therapy in Patients With Solid Tumors
Role: lead
Study of Sargramostim in Patients With COVID-19
Role: lead
Sargramostim Use in COVID-19 to Recover Patient Health
Role: lead
Study to Evaluate Pharmacokinetics, Pharmacodynamics, and Safety of Sargramostim Administered Subcutaneously, Intravenously, or by Inhalation
Role: lead
All 9 trials loaded